美舒麦角（CU 32 - 085）用于治疗帕金森病。

Mesulergine (CU 32-085) in the treatment of Parkinson's disease.

作者信息

Rascol A, Montastruc J L, Rascol O, Senard J M

出版信息

Clin Neuropharmacol. 1986;9(2):146-52. doi: 10.1097/00002826-198604000-00005.

DOI:10.1097/00002826-198604000-00005

Abstract

The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%) scores. The drug was found to be very effective on tremor (-71%). Mesulergine was useful in cases of inefficacy of levodopa alone or persistent intolerable side effects. The decrease in levodopa dose and the addition of mesulergine permitted a significant reduction in dyskinesia. Used as sole therapeutic agent (10.9 mg/day), mesulergine was found to be active on tremor and rigidity scores but not on akinesia or global scores. Mesulergine induced few side effects. These results show the antiparkinsonian properties of mesulergine that seem to be of significant therapeutic value in patients with tremor or in combination with levodopa.

摘要

对28例帕金森病患者研究了具有多巴胺激动特性的新药美舒麦角的长期疗效。在18例出现左旋多巴晚期副作用的患者中，加用美舒麦角（10.9毫克/天）可使总体评分（-48%）、强直评分（-62%）和运动不能评分（-37%）显著降低。发现该药对震颤非常有效（-71%）。美舒麦角在左旋多巴单独使用无效或持续存在难以耐受的副作用的情况下有用。减少左旋多巴剂量并加用美舒麦角可使异动症显著减轻。当作为单一治疗药物使用（10.9毫克/天）时，美舒麦角对震颤评分和强直评分有作用，但对运动不能评分或总体评分无作用。美舒麦角引起的副作用很少。这些结果表明美舒麦角的抗帕金森病特性在震颤患者或与左旋多巴联合使用时似乎具有显著的治疗价值。